Symptomatic Epstein-Barr virus reactivation in a patient with acute myeloid leukaemia and treatment with the monoclonal anti-CD20 antibody rituximab

Eur J Haematol. 2002 Jul;69(1):50-3. doi: 10.1034/j.1600-0609.2002.02740.x.

Abstract

In a patient with acute myeloid leukaemia, treated with several courses of chemotherapy including a fludarabine-containing regimen, severe symptoms due to Epstein-Barr virus reactivation occurred but could be successfully treated with the monoclonal anti-CD20 antibody rituximab. Depletion of viral host cells may be effective in treatment of symptoms due to Epstein-Barr virus reactivation.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / immunology
  • Antineoplastic Agents / therapeutic use*
  • Herpesvirus 4, Human / isolation & purification*
  • Herpesvirus 4, Human / physiology
  • Humans
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / immunology
  • Leukemia, Myeloid / virology*
  • Lymphocyte Depletion
  • Male
  • Rituximab
  • Virus Activation*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab